Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | S100A4 | P26447 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29311490 | 0.72 | MGLL (0.37) | ALDH1A1HTTMGLL | |
| SCHEMBL29311474 | 0.68 | MAPT (0.35) | ALDH1A1MGLL | |
| SCHEMBL31014872 | 0.68 | HTR2A (0.35) | ALDH1A1ALOX15HTTATMS100A4 | |
| SCHEMBL22402990 | 0.62 | CA12 (0.38) | ALDH1A1ALOX15HTTATMS100A4 | |
| SCHEMBL31014967 | 0.61 | PTGS2 (0.37) | ALDH1A1ALOX15HTTATMS100A4 | |
| SCHEMBL31014535 | 0.61 | F11 (0.37) | ALDH1A1 | |
| SCHEMBL31014590 | 0.60 | KAT2B (0.33) | ALDH1A1ALOX15HTTATM | |
| SCHEMBL14638096 | 0.60 | CRBN (0.48) | ALDH1A1 | |
| SCHEMBL29311484 | 0.55 | — | — | |
| SCHEMBL2541490 | 0.54 | IDO1 (0.60) | ALDH1A1HTTIDO1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | ALDH1A1 3112/4885ALOX15 246/4885HTT 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.